TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

Ahmad A Tarhini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.